Letter to the Editor

Cooley, L. A. , & Lewin, S. R. (2003). HIV-1 cell entry and advances in viral entry inhibitor therapy. Journal of Clinical Virology, 26(2), 121-132.

Eckert, D. M. , & Kim, P. S. (2001). Design of potent inhibitors of HIV- 1 entry from the gp41 N-peptide region. Proceedings of the National Academy of Science, 98, 11187-11192.

Eron J. , Merigan T. , Kilby M. , Yangco B. , Gleavy J. , Rusnak P. , et al. (2001, February). A 14-day assessment of the safety, pharmacokinetics and antiviral activity of T-1249, a peptide inhibitor of membrane fusion. Abstract 14. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago.

Lalezari, J. P. , Eron, J. J. , Carlson M. , Cohen C. , DeJesus E. , Arduino, R. C. , et al. (2003). A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS, 17(5), 691-698.

Lalezari, J. P. , Henry K. , O’Hearn M. , Montaner, J. S. , Piliero, P. J. , Trottier B. , et al. (2003). Enfuvirtide, an HIV- 1 fusion inhibitor, for drug-resistant HIV infection in North and South America. New England Journal of Medicine. 348(22), 2175-2185. Retrieved March 13, 2003, from http://www.nejm.org

Root, M. J. , Kay, M. S. , & Kim, P. S. (2001). Protein design of an HIV- 1 entry inhibitor. Science, 291, 884-888.